Ensign Peak Advisors
DICE

Ensign Peak Advisors’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Ensign Peak Advisors’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,177
Closed -$227K – 2305
2022
Q3 		$227K Buy
+11,177
New +$204K ﹤0.01% 1827

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Ensign Peak Advisors's DICE Position: Q4 2022 in Review

Ensign Peak Advisors sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q4 2022, closing a stake of 11,177 shares — an estimated $227K sold.

Ensign Peak Advisors first reported a position in DICE in Q3 2022 and held it in 1 quarter. The position peaked at $227K in Q3 2022. 109 funds tracked by Wall St. Rank hold DICE as of Q4 2022.

  • Ensign Peak Advisors reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 11,177 DICE Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $227K.
  • Ensign Peak Advisors first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Ensign Peak Advisors's DICE Therapeutics, Inc. Common Stock position peaked at $227K in Q3 2022.
  • 109 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.